Insilico Medicine
company · industry · UAE / USA / China
Composite score: 93.8
Rubric
output_volume
5/5
quality_median
4/5
breadth
5/5
openness
4/5
industry_uptake
5/5
longevity
5/5
translational_signal
5/5
Profile
Initiatives hosted
- ScienceAIBench — hosts 227 benchmarks
- InsilicoBench — hosts 162 benchmarks
- Drug Discovery Benchmarks (DDB) — hosts 206 benchmarks
Primary benchmarks authored / maintained
- MOSES — 72.4
- Longevity Benchmark (Insilico) — 90.6
- TargetBench (Insilico) — 84.6
- ClinBench Quarterly (Insilico) — 81.5
- ISM Benchmarks: GPCRs (Insilico) — 87.6
- ISM Benchmarks: ADMET (Insilico) — 84.6
- Polaris Biologics (Polyreactivity / SEC / Tm) — 79.0
Experts
Notes
Clinical-stage AI drug discovery company with INS018_055 in Phase 2 (IPF) and 11+ programs. Released ScienceAIBench / InsilicoBench / DDB with 200+ live benchmarks each — covering a unique longevity slice that no other org provides. Frontier-LLM leaderboards are externally benchmarked (not self-referential). Translational signal: clinical-stage pipeline. #1 in aging/longevity biotech.